Somewhat Favorable Media Coverage Somewhat Unlikely to Affect SAGE Therapeutics (SAGE) Stock Price
Headlines about SAGE Therapeutics (NASDAQ:SAGE) have trended somewhat positive on Friday, according to Accern. Accern identifies negative and positive news coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. SAGE Therapeutics earned a media sentiment score of 0.18 on Accern’s scale. Accern also assigned news headlines about the biopharmaceutical company an impact score of 46.7499064093937 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
These are some of the headlines that may have effected Accern’s rankings:
- SAGE Therapeutics (SAGE) Given a $220.00 Price Target at Canaccord Genuity (americanbankingnews.com)
- SAGE Therapeutics Inc (SAGE) Forecasted to Post Q2 2018 Earnings of ($1.86) Per Share (americanbankingnews.com)
- SAGE Therapeutics (SAGE) Coverage Initiated at Piper Jaffray Companies (americanbankingnews.com)
- Stifel Nicolaus Raises SAGE Therapeutics (SAGE) Price Target to $239.00 (americanbankingnews.com)
- SAGE Therapeutics, Inc. (SAGE) CEO Jeffrey Jonas on Q2 2018 Results – Earnings Call Transcript (seekingalpha.com)
A number of equities analysts have weighed in on the stock. Canaccord Genuity set a $220.00 target price on shares of SAGE Therapeutics and gave the company a “buy” rating in a research note on Wednesday. Stifel Nicolaus raised their target price on shares of SAGE Therapeutics from $198.00 to $239.00 and gave the company a “buy” rating in a research note on Tuesday. Piper Jaffray Companies assumed coverage on shares of SAGE Therapeutics in a research note on Monday. They set an “overweight” rating and a $206.00 target price for the company. BidaskClub downgraded shares of SAGE Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Friday, July 27th. Finally, Morgan Stanley raised their target price on shares of SAGE Therapeutics from $225.00 to $228.00 and gave the company an “overweight” rating in a research note on Friday, July 13th. Two investment analysts have rated the stock with a sell rating, fifteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. SAGE Therapeutics presently has an average rating of “Buy” and a consensus price target of $199.19.
SAGE Therapeutics (NASDAQ:SAGE) last announced its quarterly earnings results on Tuesday, August 7th. The biopharmaceutical company reported ($0.36) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.84) by $1.48. The firm had revenue of $90.00 million for the quarter. research analysts forecast that SAGE Therapeutics will post -8.54 EPS for the current fiscal year.
About SAGE Therapeutics
Sage Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system disorders. Its lead product candidate comprises brexanolone, a proprietary intravenous formulation of allopregnanolone that has completed III clinical trials for the treatment of post-partum depression (PPD).
Receive News & Ratings for SAGE Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SAGE Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.